Contact Firm
Technical Discipline

Medical Device & Pharmaceutical IP

Navigating the intersection of complex biological sciences, FDA regulatory frameworks, and global subject matter eligibility. We deliver elite patent prosecution and freedom-to-operate counsel for life sciences innovators.

✓ Clinical & Formulation Expertise ✓ MedTech & Diagnostic Arrays ✓ Hatch-Waxman Strategy
Medical Arts Inquiry

Consult with a Medical/Pharma Specialist

Protected under Attorney-Client Privilege. Strict Confidentiality Assured.

Sector Leadership

Medical & Pharma Lead Partners

Thomas Rosselli - WRC IP Law
Thomas Rosselli Senior Partner MedArts, Pharma, & Chemistry
Seth Cannon - WRC IP Law
Seth Cannon Senior Partner MedTech & Electromechanical

Navigating Complexity in the Life Sciences Landscape

Protecting innovation within the medical and pharmaceutical sectors requires more than legal knowledge—it demands an intrinsic understanding of molecular biology, organic chemistry, clinical development pathways, and FDA regulatory interdependencies. Weber Rosselli & Cannon LLP provides life sciences companies, biotech ventures, and research institutions with sophisticated intellectual property counsel designed to maximize claim scope while maintaining defensibility against future generic challenges.

Our attorneys speak the exact scientific language of your research teams. With backgrounds spanning pharmacology, chemistry, and biomechanical engineering, we rapidly digest primary research documentation, allowing us to draft multi-layered patent specifications that anticipate competitor workarounds and regulatory shifts.

Pharmaceutical & Therapeutics Prosecution

In the pharmaceutical domain, securing robust patent protection extends far beyond the active pharmaceutical ingredient (API). Our practice encompasses the full lifecycle of drug development, including novel formulations, drug delivery systems, crystalline polymorphs, dosage regimens, combination therapies, and specialty chemical synthesis.

By anticipating Paragraph IV challenges and navigating the complexities of the Hatch-Waxman Act, we help clients construct "patent thickets" around commercially critical therapeutics. We are expert at overcoming specialized USPTO rejections under 35 U.S.C. 103 (obviousness) and 112 (enablement and written description) common in unpredictable arts.

"Life sciences IP must be positioned for the future. Claims drafted today must withstand the hostile scrutiny of Hatch-Waxman litigation or PTAB proceedings a decade from now."

Medical Devices & medTech Innovation

The MedTech landscape is defined by rapid electromechanical convergence. Our firm represents clients innovating in cardiovascular devices, minimally invasive surgical robotics, diagnostic imaging systems, orthopedic implants, smart patient monitoring systems, and bio-compatible materials.

We assist MedTech firms with rigorous freedom-to-operate (FTO) clearance searches and landscaping analyses prior to product launch, ensuring their innovations do not infringe active third-party claims. When potentially blocking patents are identified, we provide actionable design-around counseling or author authoritative non-infringement and invalidity opinions.

Specialized Discipline Coverage

  • Biotechnology & Genetics: Nucleic acid sequences, antibodies, and cellular therapies.
  • Small Molecule Chemistry: API, crystalline forms, Markush structures, and intermediates.
  • Formulation & Drug Delivery: Controlled release, nanoparticle systems, and topical/injectable formulations.
  • Diagnostics & Medical Devices: Diagnostic arrays, surgical instruments, robotics, and wearables.
Impact

Representative Medical & Pharma Successes

Diagnostic Array Claim Defense

Challenge: A Series C diagnostic startup faced critical prior art rejections at the USPTO on their foundational bio-sensor array, threatening a critical Series D funding round.

Strategy & Outcome: WRC specialists conducted an Examiner Interview and drafted amendments focusing claim scope on specific bio-compatibility coatings and synthetic binding kinetics. Patent granted with broad, commercially relevant scope, securing investor confidence for the subsequent funding round.

Therapeutic Polymorph FTO

Challenge: A biotech firm preparing a New Drug Application (NDA) identified an active competitor patent covering alternative crystalline forms of their target therapeutic.

Strategy & Outcome: Senior partners analyzed the competitor's file wrapper and reaction conditions. WRC rendered a formal Non-Infringement Opinion demonstrating that the client's commercial polymorph was technically distinct and outside the asserted claim scope, allowing the commercial launch to proceed.

Surgical Robotics Portfolio Architecture

Challenge: A robotic surgery startup needed a portfolio capable of attracting acquisition interest, covering hardware, software control, and consumable instruments.

Strategy & Outcome: WRC architected a multi-patent "thicket" covering key mechanical articulations, control software algorithms, and bio-compatible instrument attachments. The strong defensive position facilitated an advantageous acquisition by a multinational medical device corporation.